PT  - JOURNAL ARTICLE
AU  - VICI, PATRIZIA
AU  - GIOTTA, FRANCESCO
AU  - DI LAURO, LUIGI
AU  - BRANDI, MARIO
AU  - GEBBIA, VITTORIO
AU  - FOGGI, PAOLO
AU  - LORUSSO, VITO
AU  - VITUCCI, CARLO
AU  - SERGI, DOMENICO
AU  - FATTORUSO, SILVIA ILEANA
AU  - GIANNARELLI, DIANA
AU  - VIOLA, GIUDITTA
AU  - CORSETTI, SERENA
AU  - COLUCCI, GIUSEPPE
AU  - LOPEZ, MASSIMO
TI  - Multicenter Phase II Trial of First-line Docetaxel/Gemcitabine in Advanced Breast Cancer Pretreated with Adjuvant Anthracyclines
DP  - 2009 May 01
TA  - Anticancer Research
PG  - 1841--1845
VI  - 29
IP  - 5
4099  - http://ar.iiarjournals.org/content/29/5/1841.short
4100  - http://ar.iiarjournals.org/content/29/5/1841.full
SO  - Anticancer Res2009 May 01; 29
AB  - The aim of this study was to evaluate activity and tolerability of docetaxel-gemcitabine combination as first-line treatment in patients with metastatic breast cancer previously treated with adjuvant anthracyclines. Patients and Methods: Sixty-eight women received gemcitabine 1,000 mg/m2 as 30-minute infusion on days 1 and 8, and docetaxel 80 mg/m2 as 1-hour infusion on day 8, with cycles repeated every 3 weeks. Results: Objective responses were observed in 32 out of 68 evaluable patients (45%; 95% confidence interval, 35.2-58.8%). Responses were 44%, 42%, 49% in soft tissue, bone and visceral lesions, respectively, 50% /52% in HER2-positive/-negative tumors, and 50% in both ER- positive/-negative tumors. Median time to progression and overall survival were 6 and 16 months, respectively. Treatment was usually well tolerated, with grade 3-4 neutropenia in 32% - 7% of the patients, and neutropenic fever, grade 3 vomiting, mucositis and peripheral neurotoxicity in 3% of the patients. Conclusion: Gemcitabine-docetaxel combination is effective and well tolerated as first-line treatment in advanced breast cancer previously treated with adjuvant anthracyclines.